Ester Aso

4.0k citations

66 papers · 3.0k indexed · h-index 33

Impact in

Biological Psychiatry top 1%
- Tryptophan and brain disorders
Pharmacology top 0.5%
- Cannabis and Cannabinoid Research
- Cholinesterase and Neurodegenerative Diseases

Papers in ⓘ

Biological Psychiatry 7
- Tryptophan and brain disorders 7
Cellular and Molecular Neuroscience 36
- Neuroscience and Neuropharmacology Research 27
- Neurotransmitter Receptor Influence on Behavior 12

Co-authors: Isidró Ferrer (39 shared papers)Rafaël Maldonado (17 shared papers)Graciela N. Balerio (5 shared papers)Margarita Carmona (12 shared papers)Pol Andrés‐Benito (9 shared papers)Olga Valverde (5 shared papers)Andrés Ozaita (3 shared papers)Ángel Pazos (3 shared papers)
Journals: Journal of Alzheimer s Disease (10 papers)European Neuropsychopharmacology (5 papers)Journal of Neuropathology & Experimental Neurology (3 papers)Journal of Neurochemistry (3 papers)Psychopharmacology (3 papers)
Partner nations: Spain United States France

In The Last Decade

Ester Aso

65 papers receiving 3.0k citations

Peers

Countries citing papers authored by Ester Aso

Since Specialization

Citations

This map shows the geographic impact of Ester Aso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ester Aso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ester Aso more than expected).

Fields of papers citing papers by Ester Aso

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ester Aso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ester Aso. The network helps show where Ester Aso may publish in the future.

Co-authors

The 25 scholars most cited alongside Ester Aso, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ester Aso Line = papers co-authored together Ester Aso links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 66 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Cannabinoids for treatment of Alzheimerâ€™s disease: moving toward the clinic Frontiers in Pharmacology ·Ester Aso, Isidró Ferrer	2014	170
2	CB ₂ Cannabinoid Receptor Agonist Ameliorates Alzheimer-Like Phenotype in AβPP/PS1 Mice Journal of Alzheimer s Disease ·Ester Aso, Salvador Juvés, Rafaël Maldonado, Isidró Ferrer	2013	165
3	BDNF impairment in the hippocampus is related to enhanced despair behavior in CB₁ knockout mice Journal of Neurochemistry ·Ester Aso, Andrés Ozaita, Elsa M. Valdizán, Catherine Ledent, Ángel Pazos, Rafaël Maldonado, Olga Valverde	2007	155
4	Cannabis-Based Medicine Reduces Multiple Pathological Processes in AβPP/PS1 Mice Journal of Alzheimer s Disease ·Ester Aso, Álex Sánchez‐Pla, Esteban Vegas, Rafaël Maldonado, Isidró Ferrer	2014	118
5	DNA methylation map of mouse and human brain identifies target genes in Alzheimer’s disease Brain ·José V. Sánchez‐Mut, Ester Aso, Nicolas Panayotis, Ira T. Lott, Mara Dierssen, Alberto Rábano, Rocío G. Urdinguio, Agustín F. Fernández, Aurora Astudillo, José I. Martı́n-Subero, Balázs Bálint, Mario F. Fraga, Antonio Gómez, Cécile Gurnot, Jean‐Christophe Roux, Jesús Ávila, Takao K. Hensch, Isidró Ferrer, Manel Esteller	2013	113
6	Neuroinflammatory Signals in Alzheimer Disease and APP/PS1 Transgenic Mice Journal of Neuropathology & Experimental Neurology ·Irene López‐González, Agatha Schlüter, Ester Aso, Paula Garcia‐Esparcia, Belén Ansoleaga, Franc Llorens, Margarita Carmona, Jesús Rodríguez Moreno, Andrea Fuso, Manuel Portero-Otı́n, Reinald Pamplona, Aurora Pujol, Isidró Ferrer	2015	105
7	CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease Frontiers in Neuroscience ·Ester Aso, Isidró Ferrer	2016	103
8	Δ9‐tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice European Journal of Neuroscience ·Graciela N. Balerio, Ester Aso, Fernando Berrendero, Patricia Murtra, Rafaël Maldonado	2004	97
9	Amyloid Generation and Dysfunctional Immunoproteasome Activation with Disease Progression in Animal Model of Familial Alzheimer's Disease Brain Pathology ·Ester Aso, Selene Lomoio, Irene López‐González, Laura Joda, Margarita Carmona, Núria Fernández-Yagüe, Jesús Rodríguez Moreno, Salvador Juvés, Aurora Pujol, Reinald Pamplona, Manuel Portero-Otı́n, M.V. Martín, Mario Dı́az, Isidró Ferrer	2011	96
10	CB1 Agonist ACEA Protects Neurons and Reduces the Cognitive Impairment of AβPP/PS1 Mice Journal of Alzheimer s Disease ·Ester Aso, Ernest Palomer, Salvador Juvés, Rafaël Maldonado, Francisco J. Muñoz, Isidró Ferrer	2012	93
11	Neuronal Hemoglobin is Reduced in Alzheimer's Disease, Argyrophilic Grain Disease, Parkinson's Disease, and Dementia with Lewy Bodies Journal of Alzheimer s Disease ·Isidró Ferrer, Ana Gómez, Margarita Carmona, Gema Huesa, Sílvia Porta, Miquel Riera‐Codina, Marta Biagioli, Stefano Gustincich, Ester Aso	2011	92
12	Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice Psychopharmacology ·Graciela N. Balerio, Ester Aso, Rafaël Maldonado	2006	83
13	Promoter hypermethylation of the phosphatase DUSP22 mediates PKA‐dependent TAU phosphorylation and CREB activation in Alzheimer's disease Hippocampus ·José V. Sánchez‐Mut, Ester Aso, Holger Heyn, Tadashi Matsuda, Christoph Bock, Isidró Ferrer, Manel Esteller	2014	81
14	Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system Biochemical Pharmacology ·Marta Aymerich, Ester Aso, Miguel Angel Abellanas, Rosa M. Tolón, J.A. Ramos, Isidró Ferrer, Julián Romero, Javier Fernández‐Ruíz	2018	80
15	Locus coeruleus at asymptomatic early and middle Braak stages of neurofibrillary tangle pathology Neuropathology and Applied Neurobiology ·Pol Andrés‐Benito, Víctor Fernández‐Dueñas, Margarita Carmona, Luis Alfonso Escobar, Benjamı́n Torrejón-Escribano, Ester Aso, Francisco Ciruela, Isidró Ferrer	2017	75
16	Evidence for Premature Lipid Raft Aging in APP/PS1 Double-Transgenic Mice, a Model of Familial Alzheimer Disease Journal of Neuropathology & Experimental Neurology ·Noemí Fabelo, M.V. Martín, Raquel Marín, Gabriel Santpere, Ester Aso, Isidró Ferrer, Mario Dı́az	2012	68
17	Effect of Poly(propylene imine) Glycodendrimers on β-Amyloid Aggregation in Vitro and in APP/PS1 Transgenic Mice, as a Model of Brain Amyloid Deposition and Alzheimer’s Disease Biomacromolecules ·Oxana Klementieva, Ester Aso, Damien Filippini, Núria Benseny‐Cases, Margarita Carmona, Salvador Juvés, Dietmar Appelhans, Josep Cladera, Isidró Ferrer	2013	67
18	Lack of CB₁ receptor activity impairs serotonergic negative feedback Journal of Neurochemistry ·Ester Aso, Thibault Renoir, Guadalupe Mengod, Catherine Ledent, M. Hamon, Rafaël Maldonado, Laurence Lanfumey, Olga Valverde	2009	66
19	PPARγ agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer’s disease: in vitro and in vivo studies International Journal of Nanomedicine ·Marcelle Silva-Abreu, Ana Cristina Calpena, Pol Andrés‐Benito, Ester Aso, Ignacio A. Romero, David Roig-Carles, Radka Gromnicova, Marta Espina, Isidró Ferrer, María L. García, David Male	2018	64
20	Poly(propylene imine) dendrimers with histidine-maltose shell as novel type of nanoparticles for synapse and memory protection Nanomedicine Nanotechnology Biology and Medicine ·Ester Aso, Isak Martinsson, Dietmar Appelhans, Christiane Effenberg, Núria Benseny‐Cases, Josep Cladera, Gunnar K. Gouras, Isidró Ferrer, Oxana Klementieva	2019	64

About Ester Aso

Ester Aso is a scholar working on Biological Psychiatry, Cellular and Molecular Neuroscience, Pharmacology, Physiology and Neurology, having authored 66 papers that have together received 3.0k indexed citations. Recurring topics across this work include Neuroscience and Neuropharmacology Research (27 papers), Cannabis and Cannabinoid Research (21 papers), Alzheimer's disease research and treatments (20 papers), Neurotransmitter Receptor Influence on Behavior (12 papers), Tryptophan and brain disorders (7 papers), Neuroinflammation and Neurodegeneration Mechanisms (5 papers), GABA and Rice Research (5 papers) and Cholinesterase and Neurodegenerative Diseases (5 papers). The work is most often cited by research in Biological Psychiatry (277 citations), Pharmacology (1.3k citations), Cellular and Molecular Neuroscience (1.2k citations), Neurology (361 citations) and Physiology (873 citations). Ester Aso has collaborated with scholars based in Spain, United States and France. Frequent co-authors include Isidró Ferrer, Rafaël Maldonado, Graciela N. Balerio, Margarita Carmona, Pol Andrés‐Benito, Olga Valverde, Andrés Ozaita, Ángel Pazos, Catherine Ledent and Irene López‐González. Their work appears in journals such as Journal of Alzheimer s Disease, European Neuropsychopharmacology, Journal of Neuropathology & Experimental Neurology, Journal of Neurochemistry and Psychopharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact